Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth
Open Access
- 29 July 2002
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (16) , 10665-10670
- https://doi.org/10.1073/pnas.162236599
Abstract
Overexpression of urokinase plasminogen activator (uPA) in endothelial cells can decrease intravascular thrombosis. However, expression of uPA is increased in atherosclerotic human arteries, which suggests that uPA might accelerate atherogenesis. To investigate whether elevated uPA expression accelerates atherogenesis, we cloned a rabbit uPA cDNA and expressed it in carotid arteries of cholesterol-fed rabbits. uPA gene transfer increased artery-wall uPA activity for at least 1 week, with a return to baseline by 2 weeks. One week after gene transfer, uPA-transduced arteries were constricted, with significantly smaller lumens and thicker walls, but no difference in intimal or medial mass. Two weeks after gene transfer, uPA- and control-transduced arteries were morphologically indistinguishable. By 4 weeks, however, uPA-transduced arteries had 70% larger intimas than control-transduced arteries (P < 0.01) and smaller lumens (P < 0.05). Intimal lesions appeared to be of similar composition in uPA- and control-transduced arteries, except that degradation of elastic laminae was evident in uPA-transduced arteries. These data suggest that elevated uPA expression in atherosclerotic arteries contributes to intimal growth and constrictive remodeling leading to lumen loss. Antagonists of uPA activity might, therefore, be useful in limiting intimal growth and preventing constrictive remodeling. Overexpression of uPA in endothelial cells to prevent intravascular thrombosis must be reconsidered, because this intervention could worsen underlying vascular disease.Keywords
This publication has 36 references indexed in Scilit:
- Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implicationsCardiovascular Research, 2000
- Optimizing Vascular Gene Transfer of Plasminogen Activator Inhibitor 1Human Gene Therapy, 1999
- Novel arterial pathology in mice and humans hemizygous for elastin.Journal of Clinical Investigation, 1998
- Overexpression of transforming growth factor β1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasiaProceedings of the National Academy of Sciences, 1998
- Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formationNature Genetics, 1997
- Plasminogen Activator Expression in Human Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Plasminogen Activator System in Human Coronary AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Quantification of Plasminogen Activators and Their Inhibitors in the Aortic Vessel Wall in Relation to the Presence and Severity of Atherosclerotic DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- The 84‐kDa Form of Human Matrix Metalloproteinase‐9 Degrades Substance P and GelatinJournal of Neurochemistry, 1995
- Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity.The Journal of cell biology, 1990